Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Core Viewpoint - Benitec Biopharma Inc. is set to provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301, which is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD) [1]. Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focused on developing novel genetic medicines [3]. - The company utilizes a proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform that combines RNA interference with gene therapy [3]. - This platform aims to create therapeutics that can silence disease-causing genes while delivering wildtype replacement genes in a single administration [3]. - Benitec is developing therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD) [3]. Webcast Information - A webcast to discuss the update on the clinical study will take place on November 3, 2025, at 8:00 am EST [2].